2026-09-21 · KeXinMaterials Redaktionsteam

EU GDP 2013/C 343/01 + WHO TRS 961 + ICH Q1A Pharma-Kählkette Schutzkoffer B2B-Leitfaden

EU GDP 2013/C 343/01 (Leitlinien vom 5. November 2012 zur Guten Vertriebspraxis von Arzneimitteln für menschliche Anwendung), WHO TRS 961 Anhang 9 (Stabilitätsprüfung pharmazeutischer Produkte) und ICH Q1A (Stabilitätsprüfung neuer Arzneistoffe und Produkte) sind die drei primären regulatorischen Instrumente für Pharma-Kählkette. Im Folgenden der 2026 B2B-Beschaffungsleitfaden mit Geltungsbereich, Temperatur-Mapping, qualifizierten Versandsystemen, Containervalidierung und Schutzkoffer-Korrelation.

EU GDP 2013/C 343/01 Übersicht

EU GDP 2013/C 343/01 is the official guideline on Good Distribution Practice of medicinal products for human use. Effective from November 2013, widely referenced by EU member states and adopted globally by pharma manufacturers.

EU GDP 2013/C 343/01 scope: Wholesale distribution of medicinal products for human use (including vaccines, biologics, biosimilars, cell therapies, gene therapies). Applies to manufacturers, importers, distributors, brokers, and transport providers.

Chapter 1 (Quality Management): Pharmaceutical Quality System (PQS) per ICH Q10, document control, change control, deviation management, CAPA, risk management per ICH Q9.

Chapter 2 (Personnel): Qualified Person (QP) per EU Directive 2001/83/EC, training programs, hygiene, documented procedures.

Chapter 3 (Premises + Equipment): Warehouse qualification per ICH Q1A + WHO TRS 953, temperature mapping, calibrated monitoring equipment, backup systems.

Chapter 4 (Documentation): All activities documented and traceable. Records retained 5 years minimum.

Chapter 5 (Operations): Receipt, storage, picking, packing, dispatch. Temperature mapping + monitoring required at all stages.

Chapter 6 (Complaints + Recalls): Complaint handling, recall procedure, mock recalls, root cause investigation.

Chapter 7 (Self-Inspections): + Inside: External provider qualification, contract agreements, GDP audits.

Chapter 8 (Transport): Critical chapter for cold chain. Includes temperature monitoring during transport, qualification of transport routes, qualified shipping containers (QSC), risk-based approach for ambient + cold transports.

Chapter 9 (Specific Provisions for Brokers): Brokers register, qualification, GDP compliance.

Annex 1 (Temperature-Controlled Distribution): Detailed requirements for refrigerated (2°C to 8°C), frozen (-15°C to -25°C), ultra-cold (-60°C to -90°C, mRNA vaccines), controlled room temperature (CRT, 15°C to 25°C).

Annex 2 (Transport by Sea / Air / Road / Rail): Specific provisions for each.

B2B relevance: All B2B suppliers of pharma transport equipment, including protective cases, must comply with EU GDP Chapter 8 + Annex 1 + Annex 2 when supplying to EU market.

B2B recommendation: For 2026 EU pharma-bound B2B orders, target EU GDP 2013/C 343/01 Chapter 8 + Annex 1 compliance: temperature mapping data, qualified shipping container validation report, transport risk assessment, deviation procedure, GDP audit access.

WHO TRS 961 Anhang 9 Stabilitätsprüfung

WHO TRS 961 (Technical Report Series 961) Annex 9 covers stability testing of pharmaceutical products, including storage conditions, container-closure systems, and packaging materials.

WHO TRS 961 Annex 9 scope: Active pharmaceutical ingredients (APIs), finished pharmaceutical products (FPPs), biologicals, vaccines, cell therapies. Applies to manufacturers globally, especially WHO-prequalified products.

Storage conditions per WHO TRS 961: Long-term (25°C ± 2°C / 60% RH ± 5% RH OR 30°C ± 2°C / 65% RH ± 5% RH for hot climates), Intermediate (30°C ± 2°C / 65% RH ± 5%), Accelerated (40°C ± 2°C / 75% RH ± 5%), Refrigerated (5°C ± 3°C), Frozen (-20°C ± 5°C).

Container-closure system: Must protect product from moisture, oxygen, light, microbial contamination, mechanical stress. Inner protective case may be part of container-closure system if product is transported in it.

Packaging materials: Must be compatible with product (no leaching, no adsorption, no chemical interaction). Glass, plastic, aluminum, laminated films per WHO PQS guidance.

Stability testing protocol: Long-term (minimum 12 months for new API/FPP, 24+ months for biologicals), intermediate (if long-term failure), accelerated (6 months). Photo-stability testing per ICH Q1B.

Stability indicating methods: HPLC, UPLC, GC, MS, NMR, IR, UV-Vis, particle size, dissolution, microbial limits, endotoxin (for injectables), biological activity (for biologics).

Container-closure validation: Extractables + leachables study, sealing integrity (microbial + dye ingress), moisture vapor transmission rate (MVTR), oxygen transmission rate (OTR).

Transport stress testing: WHO TRS 961 Annex 9 Section 2.3.7 recommends transport stress simulation: vibration (ASTM D4169 truck + air transport levels), drop (1.2m), compression (top load), temperature excursion (low + high).

WHO prequalified vaccines: WHO PQS (Performance, Quality and Safety) specification for vaccine transport containers. PQS E001 (cold box), PQS E002 (vaccine carrier), PQS E003 (ice pack), PQS E004 (temperature monitor).

B2B relevance: For B2B suppliers of pharma transport equipment, WHO TRS 961 Annex 9 specifies container validation requirements (extractables, leachables, transport stress testing). Critical for vaccine + biologics transport.

B2B recommendation: For 2026 WHO-prequalified pharma B2B orders, target WHO TRS 961 Annex 9 compliance: transport stress testing (ASTM D4169), container-closure validation report, extractables + leachables data, photo-stability data, WHO PQS specification if vaccines.

ICH Q1A Stabilitätsprüfung

ICH Q1A (R2) Stability Testing of New Drug Substances and Products is the international guideline adopted by EU + USA + Japan regulatory agencies (FDA, EMA, PMDA). Critical for global pharma market access.

ICH Q1A scope: New drug substances (APIs) and new drug products (FPPs). Pharmaceutical dosage forms (oral solid, oral liquid, parenteral, topical, inhalation, etc.).

ICH Q1A storage conditions: Long-term (25°C ± 2°C / 60% RH ± 5% RH, OR 21°C if justified), Intermediate (30°C ± 2°C / 65% RH ± 5%), Accelerated (40°C ± 2°C / 75% RH ± 5%), Refrigerated (5°C ± 3°C), Frozen (-20°C ± 5°C).

Testing frequency: Long-term (0, 3, 6, 9, 12, 18, 24, 36 months + annual thereafter), Accelerated (0, 1, 2, 3, 6 months), Intermediate (0, 3, 6, 9, 12, 18, 24, 36 months).

Stress testing: Acid, base, oxidation, photolysis (per ICH Q1B), thermal (60°C dry heat), humidity (75% RH), freeze-thaw cycles. Determines degradation pathways.

Container-closure system: Must protect product integrity throughout shelf life. Inner protective case must be evaluated for extractables + leachables.

Stability commitment: Annual batches placed in long-term stability for full shelf life (typically 24-60 months).

Packaging interactions: Glass (Type I, II, III per USP), plastic (HDPE, LDPE, PP, PET, PVC), aluminum (foil, blister), laminated films. Each evaluated for compatibility.

Data evaluation: Trend analysis, statistical analysis, specification limits (per ICH Q6A), shelf life determination, storage recommendation.

ICH regions: EU (EMA), USA (FDA), Japan (PMDA), Canada (Health Canada), Switzerland (Swissmedic), Singapore (HSA), Taiwan (TFDA), Brazil (ANVISA), China (NMPA), Korea (MFDS). Other countries (Australia TGA, South Africa SAHPRA, India CDSCO) increasingly adopt ICH.

B2B relevance: For B2B pharma equipment manufacturers, ICH Q1A container-closure validation requirements apply to inner protective case. Critical for biologics + sterile injectables where packaging integrity is preserved.

B2B recommendation: For 2026 global pharma-bound B2B orders, target ICH Q1A R2 compliance: storage condition stability data, container-closure validation, extractables + leachables study, stress testing data, statistical analysis, ICH-region acceptance.

Qualifizierter Versandcontainer (QSC) Validierung

Qualified Shipping Container (QSC) is the standard term for transport system that maintains product temperature within specified limits throughout transport duration. QSC validation is required by EU GDP Chapter 8 + Annex 1.

QSC scope: Integrated system of insulated container + refrigerant (gel packs, dry ice, phase change material) + temperature monitor. Critical for 2-8°C, -20°C, -70°C, 15-25°C products.

Temperature mapping: QSC qualification requires temperature mapping at multiple positions within container (corners + center + top + bottom) using calibrated data loggers. Mapping done at minimum + maximum + nominal load.

Thermal performance: Must maintain temperature within limits for full expected transport duration (typically 24-96 hours). Performance validated at minimum + maximum ambient temperature.

Validation protocol: Define acceptance criteria (e.g., 2-8°C maintained for 48 hours at 35°C ambient + 5°C ambient), execute at minimum 3 replicate runs, document results, define operating range.

Re-qualification: Every 12 months OR after significant change (refrigerant change, container modification, transport route change).

Refrigerant types: Gel packs (2-8°C, 24-72 hours), dry ice (-78°C, 24-96 hours), phase change materials (-20°C, -70°C, custom profiles), insulated boxes (passive), active refrigeration (electric + battery).

Temperature monitors: Single-use USB data loggers (Sensitech TempTale, Emerson GoTrack), multi-use Bluetooth loggers (LogTag, Onset HOBO), real-time trackers (Controlant, Sensitech). Each per USP <1079> + EU GDP Chapter 8.

Stability budget: Total acceptable time out of storage condition per product (e.g., 30 minutes at 25°C for mRNA vaccines). QSC must keep total excursion time within budget.

Documentation: QSC qualification protocol + report, temperature mapping data, replicate run data, operating range definition, change control, deviation procedure.

B2B relevance: For B2B suppliers of QSC (insulated containers, refrigerant packs), validation documentation is required by EU GDP + WHO + ICH Q1A.

B2B recommendation: For 2026 pharma B2B orders, supply QSC with: qualification protocol + report, temperature mapping data, 3+ replicate run data, defined operating range, change control procedure, deviation procedure, USP <1079> compliant temperature monitors.

Temperatur-Mapping + Überwachung

Temperature mapping and monitoring are critical for cold chain integrity. EU GDP Chapter 3 + 8 + Annex 1 specify warehouse and transport mapping + monitoring requirements.

Warehouse temperature mapping: Initial mapping + re-mapping every 12 months OR after infrastructure change. Minimum 9 data loggers per zone (corners + center + top + bottom). Mapping for 1 week (or seasonal if hot + cold).

Acceptance criteria: No temperature excursion > 30 minutes outside 2-8°C / -20°C / 15-25°C limits. Mean kinetic temperature within label storage range.

Mapping report: Defined acceptance criteria, mapping protocol, logger calibration, data analysis, hot spot / cold spot identification, action plan for any excursions.

Continuous monitoring: 24/7 calibrated data loggers per zone. Alarms + escalation procedure. Battery backup for power failure. Redundant systems for critical storage.

Calibration: Annual calibration of all monitoring equipment per ISO 17025 or equivalent. Traceability to NIST or equivalent national standard.

Transport monitoring: Temperature monitor placed with each shipment. Data reviewed within 24 hours of receipt. Excursion assessment + product disposition.

Excursion management: Define allowed excursion time + temperature limits per product (stability budget). Document excursion assessment procedure. CAPA for recurring excursions.

Stability budget: Total acceptable time out of label storage per product. Critical for short-stability products (mRNA vaccines 30 min, gene therapies 1 hour, cell therapies 4 hours).

Real-time monitoring: Real-time temperature + GPS tracking for critical shipments (high-value, short-stability, orphan drugs). Onward GPS + temperature data via cellular or satellite.

Documentation: Mapping reports, calibration certificates, excursion logs, CAPA records, real-time data archives.

B2B recommendation: For 2026 pharma B2B transport equipment, supply with: warehouse + transport mapping data, monitoring equipment specifications, calibration certificates, excursion procedure, stability budget template, real-time tracking capability.

Schutzkoffer-Korrelation

Protective cases used for pharma cold chain transport must maintain product integrity (temperature + sterility + physical protection) throughout shipping duration AND comply with EU GDP + WHO TRS 961 + ICH Q1A.

Double-protection model: Outer shipping system (insulated container, active refrigeration) + inner protective case (shock + vibration + sterility). Inner case protects from mechanical stress during transit.

Temperature range: Pharma products require specific storage (2-8°C, -20°C, -70°C, 15-25°C). Inner case must not affect inner thermal barrier. Material selection critical (low thermal conductivity, no thermal bridging).

Sterility: Sterile injectables, biologics, cell therapies require inner case that maintains sterility. Sealed case with sterile barrier, sterile wrap, validated sterilization (gamma 25-50 kGy, EtO, autoclave 121°C 15 min).

Vibration + shock: Road transport (1-3 g RMS), air transport (3-5 g RMS + cargo hold turbulence), courier handling (5-10 g drop impact). Inner case must absorb without product damage.

Material selection: FDA-grade plastic (USP Class VI per USP <88>), medical-grade silicone seals, food-grade EPDM. All materials must be pharma-compatible (no leaching, no adsorption).

Light protection: Photosensitive products (retinoids, certain biologics) require amber-colored or opaque inner case. UV-blocking per ICH Q1B photo-stability testing.

Cleanability: Cleanroom-compatible (ISO Class 5 / Grade A for sterile products), wipeable surfaces, validated cleaning procedure.

Marking: Inner case marked with: product compatibility (e.g., "Compatible with 2-8°C"), sterilization status (e.g., "Gamma 25 kGy"), lot number, expiry, manufacturer, EU GDP guideline compliance statement.

Validation: Inner case validated for: thermal performance (no significant impact on outer QSC), vibration + shock (ASTM D4169), sterilization (USP <85> sterility), extractables + leachables (USP <88>, ICH Q3D), stability (ICH Q1A), transport stress (WHO TRS 961).

Quality system: ISO 9001 + ISO 13485 (medical device) for pharma-grade cases. Audit trail for every unit manufactured.

B2B recommendation: For 2026 pharma cold chain B2B orders, supply protective case with: EU GDP compliance statement, WHO TRS 961 validation report, ICH Q1A compatibility data, QSC validation, sterilization certificate, ISO 13485 certificate, lot-tracked marking, validated cleaning procedure.

FAQ

Verwandte Artikel

• DNV-ST-0377 + DNV 2.7-1 + DNV 2.7-3 Offshore-Container-Familie
• ISO 13485 Medizinprodukt QMS
• ISO 9001 + ISO 14001 + ISO 45001 Managementsystem